Syngene International Q4 net down 19 pc at Rs 147.9 cr

Contract research and manufacturing services firm Syngene International Ltd on Wednesday reported a 19 per cent decline in consolidated net profit to Rs 147.9 crore in the fourth quarter ended March 31, 2026, impacted by higher expenses and termination benefits extended to employees.

Contract research and manufacturing services firm Syngene International Ltd on Wednesday reported a 19 per cent decline in consolidated net profit to Rs 147.9 crore in the fourth quarter ended March 31, 2026, impacted by higher expenses and termination benefits extended to employees. The company had posted a consolidated net profit of Rs 183.3 crore in the corresponding quarter of the previous fiscal, Syngene International Ltd said in a regulatory filing. In the fourth quarter, expenses of Rs 25 crore (net of tax) were recognised under exceptional items related to termination benefits extended to employees in accordance with the approved policy, it added. Consolidated revenue from operations in the fourth quarter stood at Rs 1,036.5 crore as compared to Rs 1,018 crore in the year-ago period. Total expenses in the period under review were higher at Rs 856.7 crore as against Rs 796.4 crore in the corresponding period a year ago, the company said. The board of directors has recommended a final dividend of Rs 1.25 per equity share of Rs 10 for the financial year 2025-26, it said. For 2025-26, consolidated net profit was at Rs 316.7 crore as compared to Rs 496.2 crore in 2024-25, the company said. Consolidated revenue in FY26 stood at Rs 3738.7 crore as against Rs 3,642.4 crore in FY25, it added. Commenting on the performance, Syngene International MD and CEO, Peter Bains, said, ''Syngene's full-year revenue from operations grew 3 per cent, and with an EBITDA margin of 25 per cent, performance was in line with our revised full-year guidance.'' The overall numbers reflect the specific impact from a single large-molecule biologics client, with the underlying business showing steady momentum, he added.